Fu Yue, Zhang Song, Yue Qiulin, An Zaiyong, Zhao Minghan, Zhao Chen, Sun Xin, Li Kunlun, Li Baojun, Zhao Lin, Su Le
State Key Laboratory of Biobased Material and Green Papermaking, School of Bioengineering, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China.
Shandong Baoyuan Biotechnology Co., Ltd., Jinan, China.
Front Microbiol. 2024 Jul 17;15:1404652. doi: 10.3389/fmicb.2024.1404652. eCollection 2024.
Sepsis is a syndrome of organ dysfunction caused by a dysregulated host response to infection and septic shock. Currently, antibiotic therapy is the standard treatment for sepsis, but it can lead to drug resistance. The disturbance of the gut microbiota which is affected by sepsis could lead to the development of organ failure. It is reported that probiotics could shape the gut microbiota, potentially controlling a variety of intestinal diseases and promoting whole-body health.
In this study, we evaluated the preventive effects of intra- and extracellular products of probiotics on sepsis. The extracellular products of () were identified through the cell experiments. The preventive effect and mechanism of extracellular products on mouse sepsis were further explored through HE staining, mouse survival rate measurement, chip analysis, etc.
extracellular products increase cell survival and significantly reduce inflammatory factors secreted in a cellular sepsis model. In experiments in mice, our samples attenuated sepsis-induced pulmonary edema and inflammatory infiltrates in the lungs of mice, and reduced mortality and inflammatory factor levels within the serum of mice. Finally, the mechanism of sepsis prevention by lactic acid bacteria is suggested. Extracellular products of could effectively prevent sepsis episodes.
In animal experiments, we reported that extracellular products of can effectively prevent sepsis, and preliminarily discussed the pathological mechanism, which provides more ideas for the prevention of sepsis. In the future, probiotics may be considered a new way to prevent sepsis.
脓毒症是一种由宿主对感染和感染性休克的反应失调引起的器官功能障碍综合征。目前,抗生素治疗是脓毒症的标准治疗方法,但它可能导致耐药性。受脓毒症影响的肠道微生物群紊乱可能导致器官衰竭的发展。据报道,益生菌可以塑造肠道微生物群,潜在地控制各种肠道疾病并促进全身健康。
在本研究中,我们评估了益生菌的细胞内和细胞外产物对脓毒症的预防作用。通过细胞实验鉴定了()的细胞外产物。通过苏木精-伊红染色、小鼠存活率测量、芯片分析等进一步探讨了细胞外产物对小鼠脓毒症的预防作用及其机制。
在细胞脓毒症模型中,细胞外产物提高细胞存活率并显著降低分泌的炎症因子。在小鼠实验中,我们的样本减轻了脓毒症诱导的小鼠肺水肿和肺部炎症浸润,并降低了小鼠血清中的死亡率和炎症因子水平。最后,提出了乳酸菌预防脓毒症的机制。的细胞外产物可以有效预防脓毒症发作。
在动物实验中,我们报道了的细胞外产物可以有效预防脓毒症,并初步探讨了其病理机制,这为脓毒症的预防提供了更多思路。未来,益生菌可能被认为是预防脓毒症的一种新方法。